Onyx, S*BIO deal

Onyx declined to exercise an option to license exclusive North American and European rights to the oral Janus kinase-2 (JAK-2) inhibitors SB1518 and SB1578 from S*BIO. SB1518 has completed Phase II testing for myelofibrosis, with pivotal trials slated for this year. The compound is also in Phase II testing for advanced lymphoid malignancies. SB1578 is in Phase I testing. Onyx, which received the option in 2009, holds an undisclosed stake in S*Bio (see BioCentury, Jan. 12, 2009). S*BIO said it will evaluate all potential alternatives, including collaboration opportunities, to maximize the value of the compounds. ...